Anti-West Nile Virus (Clone: WNV-99) – Purified No Carrier Protein

Anti-West Nile Virus (Clone: WNV-99) – Purified No Carrier Protein

Product No.: LT567

- -
- -
Product No.LT567
Clone
WNV-99
Target
West Nile virus
Product Type
Recombinant Monoclonal Antibody
Alternate Names
WNV
Isotype
Human IgG1
Applications
ELISA
,
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
West Nile
Virus
Expression Host
HEK-293 Cells
Immunogen
B cells were isolated and sequenced from an individual previously infected with a laboratory-confirmed, symptomatic WNV infection whose serum reacted to recombinant WNV NS12.
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC and SDS-Page
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Standard Overnight on Blue Ice.
Additional Applications Reported In Literature ?
ELISA
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
WNV-99 activity is directed against the wing, flexible loop of NS1. During the screening phase and post characterization clone WNV-99 was found to bind to solid-phase recombinant WNV NS1 protein and to NS1 expressed on the surface of intact WNV-infected Vero cells. Plus, also engaged the hexameric form of NS1. WNV-99 was cross-reactive against Japanese Encephalitis Virus and Tick-borne Encephalitis Virus in a direct ELISA using recombinant NS1 proteins.

Background
West Nile Virus (WNV) is a mosquito-borne, enveloped, positive-stranded RNA flavivirus1. Flavivirus nonstructural protein NS1 has been proposed as an antibody target to avoid antibody-dependent enhancement2. NS1 is a 46-55 kDa glycoprotein that is expressed as a dimer on the cell surface and as a soluble hexamer in the extracellular space and in circulation during infection. WNV NS1 dimer consists of a ß-roll, wing, and ß-ladder.

Research Area
Category B Pathogens
.
Infectious Disease
.
Viral
.
West Nile
.
IVD Raw Material

References & Citations

1. Goo L, Debbink K, Kose N, et al. Nat Microbiol. 4(1):71-77. 2019.
2. Wessel AW, Doyle MP, Engdahl TB, et al. mBio. 12(5):e0244021. 2021.
Indirect Elisa Protocol
Flow Cytometry

Certificate of Analysis

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.